Issued 2026-08-13 at $2.70 · now $2.63 (2026-08-13, −2.6% since)
Based on its own history, a month from the 2026-08-13 close, GNLX has typically landed between $1.65 and $4.08 — a range of −38.9% to +51.2% from the issuance price $2.70.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
868 overlapping 1 month windows · 2023-01-26 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($2.70) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where GNLX has typically landed a month from the 2026-08-13 close of $2.7 — the range is history, not a prediction.
- now $2.63 (-2.6%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $2.63 (-2.7%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.18–$3.07
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.65–$4.08
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2024-05-21 | −59.0% | −59.0% | +0.0% |
| 2024-05-22 | −53.1% | −57.6% | +0.0% |
| 2024-05-23 | −50.9% | −55.2% | +0.0% |
| 3 best | |||
| 2023-02-03 | +405.6% | +0.0% | +405.6% |
| 2023-02-16 | +374.5% | +0.0% | +374.5% |
| 2023-02-02 | +365.4% | −5.1% | +365.4% |
868 overlapping windows · 2023-01-26 – 2026-08-13 · not cherry-picked
Pending catalysts
- December 2026 — Trial primary completion: Phase 3 primary completion: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (source, as of 2026-08-14)
- February 2027 — Trial primary completion: Phase 2 primary completion: Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~4 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.